Glybera's additional benefits not quantifiable, says Germany
This article was originally published in Scrip
Executive Summary
The additional benefits of Chiesi/UniQure's orphan drug Glybera are not quantifiable, says the G-BA, the body in charge of Germany's AMNOG benefit assessments for new pharmaceuticals. The news comes after the G-BA last month slammed Chiesi for failing to properly disclose a potentially damming report from the European Medicines Agency.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.